PepGen Inc. (NASDAQ:PEPG - Get Free Report) CEO James G. Mcarthur acquired 41,500 shares of PepGen stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average price of $1.15 per share, with a total value of $47,725.00. Following the transaction, the chief executive officer now owns 103,913 shares in the company, valued at approximately $119,499.95. This represents a 66.49 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
PepGen Price Performance
Shares of PEPG opened at $1.13 on Thursday. The stock has a market cap of $36.94 million, a price-to-earnings ratio of -0.38 and a beta of 1.42. The company has a 50-day moving average of $1.70 and a two-hundred day moving average of $4.14. PepGen Inc. has a one year low of $0.88 and a one year high of $19.30.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.13. Analysts anticipate that PepGen Inc. will post -2.73 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Bank of America cut shares of PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a report on Monday, December 16th. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of PepGen in a report on Monday, February 24th.
Get Our Latest Research Report on PEPG
Institutional Trading of PepGen
Several institutional investors have recently made changes to their positions in the stock. RTW Investments LP acquired a new stake in shares of PepGen during the fourth quarter worth approximately $12,102,000. Northern Trust Corp raised its position in PepGen by 5.4% during the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company's stock valued at $595,000 after acquiring an additional 7,984 shares in the last quarter. Millennium Management LLC raised its position in PepGen by 1,033.2% during the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company's stock valued at $594,000 after acquiring an additional 142,814 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in PepGen during the fourth quarter valued at approximately $516,000. Finally, Bridgeway Capital Management LLC raised its position in PepGen by 103.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company's stock valued at $375,000 after acquiring an additional 50,200 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors and hedge funds.
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
